SAN DIEGO, September 25, 2019
–Qpex Biopharma today announced scientific presentations on its
investigational anti-infectives at the IDWeek 2019 Conference to be held
October 2-6 in Washington, DC.
Qpex scientists and external collaborators will be making the first public presentations on QPX9003, a next generation polymyxin antibiotic for multi-drug resistantAcinetobacter and Pseudomonas aeruginosa. In addition, they will present new data on the ultra-broad-spectrum beta-lactamase inhibitor QPX7728, focusing on its first-in-class properties as an inhibitor with potent activity with multiple beta-lactam antibiotics in Acinetobacter and Pseudomonas, as well as in Enterobacteriaceae that produce serine and metallo beta-lactamases.
“We are pleased to report new data at IDWeek on our clinical candidates that demonstrate compelling preclinical properties as best-in-class agents forAcinetobacter, Pseudomonas, and Enterobacteriaceae,” said Michael Dudley, PharmD, FIDSA, President and CEO of Qpex Biopharma. “We welcome the opportunity to engage with the infectious disease community on the excellent progress of these programs as part of our ongoing portfolio collaboration with BARDA,”he added.
poster presentations on the microbiological properties of QPX7728, and
two posters on the microbiological properties and preclinical
pharmacology of the clinical candidate QPX9003 will be presented by Qpex
scientists and external collaborators. Data show that QPX7728 has
potent inhibition of clinically important beta-lactamases from Classes
A, B, C, and D that are often present in multi-drug resistant (MDR)Acinetobacter, Pseudomonas,
and Enterobacteriaceae. Notably, QPX7728 is active in strains of
carbapenem-resistant Enterobacteriaceae (CRE) with resistance to
ceftazidime-avibactam. The two posters on QPX9003 will show its improved
potency and therapeutic index for Acinetobacter and Pseudomonas aeruginosa in animal models over polymyxin B.
About Qpex Biopharma, Inc.
Qpex Biopharma (www.qpexbio.com) is a San Diego-based biopharmaceutical company with a pipeline of best-in-class agents addressing critical needs for treatment of infectious diseases in the inpatient and outpatient settings. Qpex was launched in October 2018 with investments from New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners and Stanford University Draper Fund. The company’s scientists and clinicians have a record of deep expertise in the discovery and development of anti-infective agents, and an extensive record of working with public-private partnerships, including a previous contract with the Biomedical Advanced Research and Development Authority (BARDA) that led to the first approved antimicrobial drug product under that program in 2017.